SPY332.11+2.05 0.62%
DIA272.00+3.59 1.34%
IXIC10,998.40+57.23 0.52%
News
PACB
--
0.00%
--
What's Behind Pacific Biosciences of California's Ugly Q2 Results?
It's been pretty much nothing but bad news from Pacific Biosciences of California (NASDAQ: PACB) (PacBio) so far in 2020. Even after rebounding from its March lows, the stock is still down more than 20% year to date.
Motley Fool · 1d ago
Pacific Biosciences of California (PACB) Q2 2020 Earnings Call Transcript
PACB earnings call for the period ending June 30, 2020.
Motley Fool · 1d ago
Pacific Bio Q2 top line down 31% but above views
Pacific Biosciences of California (NASDAQ:PACB) Q2 results: Revenue: $17.1M (-30.5%); product sales: $13.8M (-35.2%) due to pandemic disruptions. Net loss:
seekingalpha · 2d ago
Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 21.05% and 23.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 2d ago
Pacific Biosciences Q2 EPS $(0.15) Beats $(0.18) Estimate, Sales $17.10M Beat $13.72M Estimate
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.18) by 16.67 percent. This is a 6.25 percent increase over losses of $(0.16) per share
Benzinga · 2d ago
Pacific Biosciences of California, Inc. Announces Second Quarter 2020 Financial Results
MENLO PARK, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its second quarter ended June 30, 2020. Total revenue for the second quarter of 2020 was $17.1 million, compared
GlobeNewswire · 2d ago
Pacific Biosciences of California shares are trading higher after the company and Asuragen announced their clinical research collaboration aimed at developed molecular assays based on PacBio's Single Molecule, Real-Time Sequencing technology.
Benzinga · 2d ago
Pacific Biosciences And Asuragen Collaborate To Develop Assays For Carrier Screening And Other Applications Based On SMRT Sequencing Technology And AmplideX PCR Chemistry
Joint research effort will lead to molecular assays that can improve variant detection and access difficult-to-sequence regions of the human genome Pacific Biosciences of California, Inc. (NASDAQ:PACB), a leading
Benzinga · 2d ago
Pacific Biosciences and Asuragen Collaborate to Develop Assays for Carrier Screening and other Applications Based on SMRT Sequencing Technology and AmplideX PCR Chemistry
Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, and Asuragen, a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and on
Business Wire · 2d ago
Analysts Estimate Pacific Biosciences of California (PACB) to Report a Decline in Earnings: What to Look Out for
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/27 16:31
Pacific Biosciences of California, Inc. Second Quarter 2020 Financial Results Call
MENLO PARK, Calif., July 24, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Second Quarter 2020 Financial Results on Monday, August 3, 2020, at 4:30pm Eastern Time. The ca
GlobeNewswire · 07/24 16:07
Hedge Funds Are Selling Pacific Biosciences of California, Inc. (PACB)
Insider Monkey · 06/23 18:21
Genomics: How A Cutting-Edge Field Is Fighting COVID-19
Seeking Alpha - Article · 06/18 13:05
Pacific Biosciences Files For $250M Mixed Security Offering
Benzinga · 06/10 20:04
Pacific Biosciences Reports Pres, CEO Michael Hunkapiller, CFO Susan Barnes To Retire; Co. Has Active Searches Underway To Find Replacements
Benzinga · 06/10 13:00
Pacific Biosciences Announces Planned Retirement of CEO, Dr. Michael Hunkapiller
Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that Michael Hunkapiller, Ph.D. is retiring as Chief Executive Officer and President by the end of the year
GlobeNewswire · 06/10 12:59
Pacific Biosciences of California, Inc. Announces Rescheduling of 2020 Annual Meeting of Stockholders and Move to Virtual Meeting
GlobeNewswire · 06/08 21:02
Pacific Biosciences (PACB) Up 8.1% Since Last Earnings Report: Can It Continue?
Zacks · 06/05 16:31
Cantor Fitzgerald Assumes Pacific Biosciences at Overweight, Announces Price Target of $5
Cantor Fitzgerald assumes Pacific Biosciences (NASDAQ:PACB) with a Overweight rating and announces Price Target of $5.
Benzinga · 06/02 11:15
Edited Transcript of PACB earnings conference call or presentation 6-May-20 8:30pm GMT
Q1 2020 Pacific Biosciences of California Inc Earnings Call
Thomson Reuters StreetEvents · 05/17 22:01